Research
Hormonal
Semaglutide 1-year persistence rates increased from 33.2% in 2021 to 58.6% in 1H 2024.
The increase in semaglutide persistence suggests improved patient adherence, which may be beneficial for weight management strategies.
StrongSupportsmedium confidence
Semaglutide 1-year persistence rates from 2021 to 1H 2024 were 33.2%, 34.1%, 39.8%, and 58.6%, respectively.
Why this rating
Based on the cohort study design with a large sample size.
Source
Trends in 1-year persistence and adherence among initiators of high-potency, weight loss–indicated glucagon-like peptide 1 receptor agonists
Landon Marshall et al. · Journal of Managed Care & Specialty Pharmacy · 2026
cohort · n=62650Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →